mrcc: impact of cabosun and checkmate-214
Published 6 years ago • 149 plays • Length 5:26Download video MP4
Download video MP3
Similar videos
-
1:32
dr. pal compares checkmate-214 and cabosun trials in rcc
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
1:33
dr. pal on the checkmate-214 and cabosun studies in rcc
-
4:18
mrcc: how an approved i-o regimen impacts treatment
-
3:16
cabosun: upfront use of cabozantinib for mrcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
12:48
checkmate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy
-
5:06
phase 3 checkmate - 214
-
10:25
for hcps: learn about the cabometyx® (cabozantinib) mechanism of action
-
14:05
checkmate-77t: perioperative nivolumab benefit for nsclc
-
32:44
nephrology: 1 diagnostic tests in nephrology conrad fischer
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
1:06
dr. mckay discusses the checkmate-214 trial in rcc
-
1:54
checkmate 214 trial in rcc updates
-
9:00
checkmate 214, keynote-564, and updates in treatment approaches to nccrcc
-
2:12
results of a trial comparing cabozantinib and sunitinib in mrcc
-
0:52
dr. choueiri on impact of cabosun results in renal cell carcinoma
-
2:02
cabozantinib in mrcc
-
1:30
targeted therapies for the treatment of mrcc after nivolumab-ipilimumab failure
-
1:21
dr. mckay on the impact of angiotensin system inhibitors on outcomes in patients with mrcc
-
1:21
rana mckay, md, considers the implications of checkmate 214 & keynote-426 presented at gu 2019